Thera-SAbDab

OPORTUZUMAB

>   Structural Summary
TherapeuticOportuzumab
TargetEPCAM
Heavy ChainEVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatscFv
Isotypena
Highest Clinical Trial (June '19)Preregistration
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2008
INN Year Recommended2009
Companies InvolvedUniversity of Zurich, National Cancer Institute (USA), Sesen Bio, Viventia Biotechnologies
Conditions Approvedna
Conditions ActiveBladder cancer, Head and neck cancer
Conditions DiscontinuedLiver cancer, Ovarian cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]